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A B S T R A C T
Background: Vitamin D deﬁciency is highly prevalent during pregnancy. It has been suggested that
vitamin D supplementation during pregnancy may reduce the risk of adverse gestational outcomes.
Objectives: To update a previous meta-analysis on the effects of oral vitamin D supplementation (alone or
in combination with other vitamins and minerals) during pregnancy on maternal 25(OH)D levels and risk
of developing pre-eclampsia, gestational diabetes, preterm birth, impaired glucose tolerance, caesarean
section, gestational hypertension and other adverse conditions.
Methods: We searched for randomized and quasi-randomized trials through the Cochrane Pregnancy and
Childbirth Group’s Trials Register, the International Clinical Trials Registry Platform, the Networked
Digital Library of Theses and Dissertations, and direct communications with relevant organizations.
Assessments of inclusion criteria, extraction of data from included studies, and risk of bias’ assessments
of the included studies were done independently by two review authors.
Results: We included 15 trials, excluded 27 trials and 23 trials are still ongoing/unpublished. Data from
seven trials with 868 women suggest that pregnant women supplemented with vitamin D had
signiﬁcantly higher 25(OH)D levels compared to controls (mean difference: 54.7 nmol/L; 95% CI 36.6,
72.9). Two trials found a lower risk of preeclampsia (8.9% versus 15.5%; average risk ratio 0.52; 95% CI
0.25, 1.05) and two other trials found no difference in the risk of gestational diabetes with vitamin D
supplementation. Also, three trials found that supplementation with vitamin D plus calcium reduced the
risk of pre-eclampsia (5% versus 9%; average risk ratio 0.51; 95% CI 0.32, 0.80).
Conclusion: Supplementing pregnant women with vitamin D led to signiﬁcantly higher levels of 25(OH)D at
term compared to placebo/control but results were inconsistent. Vitamin D supplementation, with or
without calcium, may be related to lower risk of preeclampsia but more studies are needed to conﬁrm this.
ã 2016 World Health Organization; Licensee Elsevier Ltd. This is an open access article under the CC BY-NC-
ND IGO 3.0 license (https://creativecommons.org/licenses/by-nc-nd/3.0/igo/).
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Vitamin D deﬁciency during pregnancy may be a common
health problem worldwide. A recent review including 17 studies in
pregnant and lactating women (2 in America, 6 in Europe, 1 in
Africa, 7 in Asia, 1 in Oceania) found the highest prevalence of
vitamin D deﬁciency in pregnant women from Asia [48]. The
prevalence of vitamin D deﬁciency (serum 25(OH)D levels <50
nmol/L or 20 ng/mL) was particularly high in India (60%), Turkey
(50%), Pakistan (45%), and Kuwait (38–41%). This prevalence
increases with seasonal variation, with a greater prevalence during
the winter months compared to the summer months [46,47].
Differences in latitude have also been shown to inﬂuence the
concentration of vitamin D in a majority of pregnant women [56].
Vitamin D status during pregnancy has an important effect on
the fetus as it completely relies on the maternal stores for its
growth and development. During pregnancy, 1,25(OH)2D increases
early during pregnancy and continues to increase until delivery
[44]. This large increase in 1,25(OH)2D appears to be dependent on
available 25(OH)D levels but independent on calcium metabolism,
which is a unique feature of pregnancy that allows such high levels
of 1,25(OH)2D [49]. Therefore, maintaining high enough levels of
25(OH)D are important to sustain the increased levels of 1,25
(OH)2D during pregnancy. Such levels are still yet to be determined
but studies have shown that maternal vitamin D status is
associated with various health outcomes during pregnancy.
Maternal vitamin D deﬁciency in pregnancy has been associated
with an increased risk of pre-eclampsia, a condition associated with
an increase in maternal and perinatal morbidity and mortality
[8,9,27,34,37,67]. Two meta-analyses including eight [59] and 31 [1]
studies found signiﬁcantly higher risks pre-eclampsia in women
with vitamin D deﬁciency. In addition, vitamin D deﬁciency in early
pregnancy has been associated with elevated risk for gestational
diabetes mellitus [21,70,1,66] and with caesarean section [43,54].
Some health organizations recommend vitamin D supplemen-
tation during pregnancy, ranging from 200 to 400 IU/d (5 to
10 mg/d) [11,62]. These doses may not lead to optimal serum 25
(OH)D levels during pregnancy. However, there is controversy
regarding the 25(OH)D levels that are considered adequate or
optimal for overall health and during pregnancy. The US Institute
of Medicine has determined that levels greater than 50 nmol/L or
20 ng/mL are adequate based on the current studies available
[22], although many investigators consider that optimal levels
should be higher (greater than 75 nmol/L or 30 ng/mL) [16,28]. It
has been suggested that regular supplemental dose of vitamin D
of 1000–1600 IU (25–40 mg/d) might be necessary to achieve and
maintain what many considered to be optimal levels in the body[16]. However, the dose of vitamin D needed to have an effect
during pregnancy is not clear.
Therefore, we aimed to systematically review the effects of
vitamin D supplementation during pregnancy on maternal out-
comes against no supplementation.
2. Methods
2.1. Types of studies
In this updated review, we included randomized trials of vitamin
D supplementation during pregnancy in apparently healthy
pregnant women. Detailed methods are published elsewhere [17].
Brieﬂy, we included any vitamin D dose, duration or time of
commencement of supplementation and any gestational or chrono-
logical age, parity (number of births) and number of fetuses. We
included trials testing vitamin D alone or in combination with other
micronutrients as long as the intervention and the control group
were treated similarly. We excluded studies where vitamin D was
provided by injection or studies assessing food fortiﬁcation.
2.2. Types of interventions
We included trials examining any of the following comparisons:
(1) oral vitamin D supplements alone versus no treatment/placebo
(no vitamins or minerals); (2) oral vitamin D and calcium
supplements versus no treatment/placebo (no vitamin or miner-
als); (3) oral vitamin D and calcium supplements versus oral
calcium supplements (but no vitamin D); (4) oral vitamin D,
calcium and other vitamins and minerals supplements versus oral
calcium and other vitamins and minerals supplements (but no
vitamin D); or (5) oral vitamin D and calcium and other vitamins
and minerals supplements versus other oral vitamins and minerals
supplements (but no vitamin D or calcium). Trials comparing
different doses of vitamin D supplementation only were excluded.
2.3. Outcomes
The primary outcomes were: (1) Pre-eclampsia (as deﬁned by
trialists); (2) Gestational diabetes (as deﬁned by trialists); (3)
Vitamin D status at term (25OHD in nmol/L); and Adverse events
(e.g. hypercalcaemia, kidney stones).
The secondaryoutcomes were: (1) Impaired glucose tolerance (as
deﬁned by trialists); (2) Caesarean section; (3) Gestational
hypertension (as deﬁned by trialists); and (4) Maternal death (death
while pregnant or within 42 days of termination of pregnancy).
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The search methods were based on a standard template used by
the Cochrane Pregnancy and Childbirth Group, as published earlier
[17]. We searched the Cochrane Pregnancy and Childbirth Group’s
Trials Register (23 February 2015), the World Health Organization
(WHO) International Clinical Trials Registry Platform (31 January
2015), the Networked Digital Library of Theses and Dissertations
(28 January 2015). For ongoing and unpublished studies, we
contacted different institutions, such as the WHO (Reproductive
Health and Research, Nutrition for Health and Development, and
regional ofﬁces), UNICEF, the Micronutrient Initiative, the Global
Alliance for Improved Nutrition and the US Centers for Disease
Control and Prevention. We did not apply any date or language
restrictions but we only found English language papers.
2.5. Selection of studies and data extraction
Two review authors (LL, JP) independently assessed for
inclusion criteria. All the papers were assessed in duplicate and
we resolved any disagreements through discussion or, if required,
we consulted a third author (LMD). We contacted authors in the
case of abstracts or studies with limited information. A data
extraction form was used and data was entered into Review
Manager Software [50] and checked for accuracy. Risk of bias was
assessed in each study as previously published [17].
2.6. Statistical analyses
For dichotomous data, we present results as average risk ratio
with 95% conﬁdence intervals. For continuous data, we used the
mean difference as the outcomes were measured in the same way
between trials; there was no need to use the standardized mean
difference to combine trials. For studies with more than two
intervention groups (multi-arm studies), we combined groups to
create a single pair-wise comparison [25] and included the
disaggregated data in the corresponding subgroup category. When
the control group was shared by two or more study arms, we
divided the control group (events and total population) over the
number of relevant subgroup categories to avoid double counting
the participants.
For all outcomes, we carried out analyses on an intention-to-
treat basis. The denominator for each outcome in each trial was the
number randomized minus any participants whose outcomes are
known to be missing. We assessed statistical heterogeneity in each
meta-analysis using the Tau2, I2 and Chi2 statistics. We regarded
heterogeneity as substantial if I2 was greater than 30% and either
Tau2 was greater than zero, or there was a low P value (less than
0.10) in the Chi2 test for heterogeneity. All analyses wereFig. 1. Study selecperformed using the Review Manager software [50]. Since we
detected substantial statistical heterogeneity, we used random-
effects meta-analysis to produce an overall summary of an average
treatment effect across trials. We treated the random-effects
summary as the average range of possible treatment effects and we
discussed the clinical implications of treatment effects differing
between trials.
As only one study was considered of high quality, we did not
conduct sensitivity analysis. We considered a study to be of high
quality if it was assessed as having low risk of bias in both the
randomization and allocation concealment and additionally a low
risk of bias in either blinding or losses to follow-up. In addition,
we were not able to conduct the subgroup analyses as very few
studies contributed data. As more data become available, in
updates of the review, we hope to explore possible subgroup
differences by carrying out both visual exploration and formal
statistical tests.
3. Results
3.1. Description of studies
A total of 15 studies involving 2833 women were included for this
review (Fig. 1). We excluded 27 studies, mainly because the
comparisons were among different doses of vitamin D without a
placebo or control group [7,15,24,35,40,45,51,55,57,58,29,64,65,68].
Also, four trials were not randomised [2,12,14,33] and three were
done in pregnant women with chronic conditions [3,4,20]. Three
trials were excluded for other various reasons [13,31,32,36,60,63].
We identiﬁed 16 ongoing trials.
A detailed description of each included trial is shown in Table 1.
Trials were conducted in Bangladesh [52], Brasil [19], China [34],
France [18,38], India [41,39,53], Iran [6,5,61], New Zealand [23],
Russia [42] and the United Kingdom [10]. The seasons varied
among studies with some trials occurring during the winter-spring
period [18]; winter [38]; summer [69] or in different seasons
[10,19,23,53] but most did not report the season. The sample size
from all the studies was small and ranged between 40 [18] and
400 women [41]. In all the studies women were recruited and
received the supplements at 20 or more weeks of gestation. Pre-
gestational body mass index was only reported in one trial and was
used as a stratiﬁcation criterion prior to the randomization
[6,5,19,53,61]. Most trials did not specify the ethnicity or skin
pigmentation of participants.
With respect to types of interventions (Table 1), nine trials
compared provision of oral vitamin D supplement in comparison
with placebo or no intervention [5,10,18,23,38,39,52,53] and six
trials compared oral vitamin D plus calcium supplements versus no
treatment or placebo [34,41,42,61]. The vitamin D dose used variedtion process.
Table 1
Description of included studies in the review.
Author Country Population Intervention Outcomes Measurement of
25(OH)D
[6] Republic of Iran
(latitude: 35440N;
North of the Tropic
of Cancer).
54 primigravida singleton
pregnant women at risk for pre-
eclampsia, 18–35 years old, at
their 3rd trimester.
RCT, single-blinded, with 2 arms: (1)
Vitamin D3 (200 IU/d) + calcium (500 mg/
d)(n = 27); or (2) Placebo (n = 27),
followed for 9 weeks until term.
BMI, serum 25(OH)D levels, FBG, total
cholesterol, TAG, HDL-c, LDL-c, dietary
intakes, total HDL:cholesterol ratio,
gestational diabetes, severe pre-
eclampsia, preterm delivery.
Immunoassay
(commercial
ELISA kit)
[5] Republic of Iran
(latitude: 35440N;
North of the Tropic
of Cancer).
54 pregnant women 18–
40 years old, with gestational
diabetes mellitus (diagnosed by
a 100-g oral OGTT at 24–28 wks
gestation)
RCT, double-blinded, with 2 arms: (1)
Vitamin D3 (50,000 IU) (n = 27); or (2)
Placebo (n = 27), given at baseline and at
day 21, followed for 6 weeks (Jan-April
2013). All participants were
supplemented with 400 mg/d of folic acid
and 60 mg/d of iron.
BMI, serum 25(OH)D levels, FBG;
gestational diabetes mellitus; total
glutathione; hs C-reactive protein; OGTT;
QUICKY; total antioxidant capacity;
placenta abruption, fetal death, severe
preeclampsia.
Immunoassay
(commercial
ELISA kit)
[10] London, England
(latitude: 51360N;
North of the Tropic
of Cancer)
126 Asian immigrant pregnant
women at 28–32 weeks of
gestation.
RCT, double-blinded, with 2 arms: (1)
Vitamin D2 (1000 IU/d) (n = 59); or (2)
Placebo (n = 59), followed for 8–12 weeks
until term.
Weight gain, dietary vitamin D intake,
intervention compliance, serum 25(OH)D
levels, plasma calcium, i-phosphate,
bilirubin, albumin, alkaline phosphatase
activity, vitamin D binding globulin and
others.
Competitive
protein
binding assay
[18] Lyon, France
(latitude: 45450N;
North of the Tropic
of Cancer)
40 singleton pregnant women
on their 3rd month of pregnancy
RCT, with 2 arms: (2) Vitamin D3
(1000 IU/d) (n = 20); or (2) No treatment
(n = 20); followed for 12 weeks until term
Serum 25(OH)D levels, PTH, total calcium,
ionised calcium, magnesium, inorganic
phosphate.
Competitive
protein
binding assay
[19] Rio de Janeiro,
Brazil (latitude:
23430S; North of
the Tropic of
Capricorn).
84 primigravida, singleton
pregnant adolescents (13–
19 years) with 23–29 wks of
gestation
RCT, with 2 arms: (1) Vitamin D3 (200 IU/
d) + calcium (600 mg/d) (n = 43); or (2)
Placebo (n = 41)
Serum 25(OH)D levels, PTH, IGF-I, lumbar
spine PA, bone mineral content, serum
prolactin and estradiol.
Immunoassay
(Liaison;
Diasorin)
[23] Auckland, New
Zealand (latitude:
36520S; South of
the Tropic of
Capricorn)
260 pregnant women 26–
30 wks gestation, with a
singleton pregnancy
RCT, double-blinded, with 3 arms: (1)
Vitamin D3 (1000 IU/d) (n = 87); Vitamin
D3 (2000 IU/d) (n = 86); or (3) Placebo
(n = 87), from 26–30 wks of pregnancy
until term (April 2010 to July 2011)
Serum 25(OH)D levels LC–MS
Li 2000 Xi’an, China
(latitude: 34150
N; North of the
Tropic of
Capricorn)
88 pregnant women at 20–24
weeks’ gestation and a
BMI <24 kg/m2
RCT with 3 arms: (1) Vitamin D3 (200 IU/
d) + calcium (600 mg/d) (n = 29); (2)
Vitamin D3 (400 IU/d) + calcium
(1200 mg/d) (n = 29); (3) No intervention
(n = 30), from 20–24 weeks until delivery.
Blood pressure, ionized calcium and
platelet intracellular calcium, incidence
rates of
pregnancy-induced hypertension.
Not reported
[38] Northwest of
France (latitude:
49260N; North of
the Tropic of
Cancer)
77 white pregnant women 18–
36 years of age in the last
trimester of pregnancy
RCT, double-blinded, with 3 arms: (1)
Vitamin D2 (1000 IU/d for the last
3 months of pregnancy) (n = 21); (2)
Vitamin D2 (single dose of 200,000 IU at
the 7th month of pregnancy) (n = 27); or
(3) No treatment (n = 29), followed until
term
Serum and cord blood levels of 25(OH)D
and 1,25(OH) 2D, 24-h urinary calcium
excretion, serum calcium
Competitive
protein
binding assay
[41] Rohtak, India
(latitude: 76340N;
North of the Tropic
of Cancer)
400 pregnant women 20–
35 years of age
RCT, with 2 arms: (1) Vitamin D (1200 IU/
d) + calcium (375 mg/d) (n = 200); or (2)
No supplementation (n = 200), followed
from 20–24 wks of pregnancy until term
Pre-eclampsia; systolic and diastolic
blood pressure at 24, 28, 32 and 36 weeks
of gestation; serum calcium and
creatinine.
Not assessed
[39] Rohtak, India
(latitude: 76340N;
North of the Tropic
of Cancer)
200 pregnant women, aged 22–
35 years old, singleton
RCT, with 2 arms: (1) Vitamin D (2 doses
of 600,000 IU at 7th and 8th month of
pregnancy) (n = 100); or (2) No
supplementation (n = 100), followed for
12 weeks until term
Serum calcium, proteins, i-phosphate,
alkaline phosphatase, body weight;
radiological examination; symptoms
(back age, leg-pains, general weakness,
cramps)
Not assessed
[42] Moscow, Russia
(Latitude:
55450N; North of
the Tropic of
Cancer).
72 pregnant women aged 18–
35 with low calcium
consumption ( < 600 mg/day)
RCT, with 2 arms: (1) Vitamin D3 (200 IU/
d) + calcium (1250 mg/d) (n = 43); or (2)
No intervention (n = 29), followed from
2nd trimester until term
Resistance of uterine arteries, resistance
of umbilical arteries, uterine-placental
circulation.
Not assessed
[52] Dhaka, Bangladesh
(latitude: 23510N;
At the Tropic of
Cancer)
160 pregnant women aged
18 <35 years old with
gestational age of 26–29th
week.
RCT, with 2 arms: (1) Vitamin D3
(35,000 IU/wks) (n = 80); or (2) Placebo
(n = 80), followed from 26–29 weeks until
term.
Serum 25(OH)D levels, serum calcium
concentration, urine Ca:Cr ratio.
HPLC–MS
[53] New Delhi, India
(latitude: 28380N;
180 pregnant women with
singleton pregnancy at 14–
20 week gestation.
RCT, with 2 arms: (1) no supplementation
(n = 60); (2) Vitamin D3, which depended
on initial level (single dose of 60,000 at
Serum 25(OH)D, calcium, phosphorus
and ALP levels; preterm labour, pre-
eclampsia, gestational diabetes mellitus.
Sandwich
ELISA
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Table 1 (Continued)
Author Country Population Intervention Outcomes Measurement of
25(OH)D
North of the Tropic
of Cancer)
20 weeks, 120,000 at 20 and 24 weeks or
120,000 IU at 20, 24, 28 and 32 weeks).
[61] Isfahan, Iran
(latitude: 33520N;
North of the Tropic
of Cancer)
990 nulliparous women with
singleton pregnancy before
20 weeks of gestation and
normal blood pressure
RCT, with 3 arms: (1) Aspirin (65 mg/d)
(n = 330); (2) Vitamin D3 (200 IU/
d) + calcium (500 mg/d) (n = 330); (3) no
intervention (n = 330), from week 20 until
delivery.
Blood pressure, weight, height, BMI, urine
protein, duration of gestation
Not assessed
[69] London, England
(latitude: 51360N;
North of the Tropic
of Cancer)
180 pregnant women (from
diverse ethnicity/race) at
27 wks gestation
RCT with a 4  3 block design: (1) Vitamin
D2 (800 IU/d)(n = 60); (2) Vitamin D3
(single dose of 200,000 IU) (n = 60); or (3)
No supplementation (n = 60), followed for
13 weeks until term (April-Nov 2007)
Serum and cord 25(OH)D levels at
delivery, PTH and corrected calcium
levels at delivery, adverse events
Not speciﬁed
RCT: randomized controlled trial; BMI: body mass index; TAG: triacylglyceride; FBG: fasting blood glucose; OGTT: oral glucose tolerance test; QUICKY: quantitative insulin
sensitivity check index; PTH: parathyroid hormone; IGF: insulin growth factor; HDL-c: high density lipoprotein cholesterol; LDL-c: low density lipoprotein cholesterol. LC–
MS: Liquid chromatography–mass spectrometry; HPLC–MS: high-Performance liquid chromatography-mass spectrometry.
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400 IU [5,34]; 800 IU [69], 1000 IU [10,18,23,38]; 1200 IU [41] to
2000 IU [23]. Among the trials using large single doses, the dose
varied from 50,000 IU [5]; 200,000 IU [69]; 60,000–480,000 IU
[53]; 600,000 IU [39] to 35,000 IU vitamin D per week [52]. The
type of vitamin D used in most trials was cholecalciferol-D3, with
only three trials using ergocalciferol-D2 [10,38,69]. However, the
form used was not reported in two of the trials [41,39].
Different laboratory methods were used to measure vitamin D
status as serum 25(OH)D levels (Table 1). Only two trials used mass
spectrometry [23,52]. The other trials used commercially available
kits. However, four trials did not report the laboratory method used
or if it was measured [69,41,39,42].
3.2. Oral vitamin D alone supplements versus no treatment/placebo
(no vitamins or minerals)
Nine studies involving 1251 women were included in this
comparison [5,10,18,23,39,52,53,69].
With respect to maternal vitamin D levels at term, data from
seven trials [5,10,18,38,52,53,69] with 868 women showed that
vitamin D supplementation signiﬁcantly increased 25(OH)D levels
compared to placebo/control group, with a mean difference of
54.7 nmol/L (95% CI 36.6, 72.9) (Fig. 2). This response was highly
heterogeneous (Tau2 = 216, I2 = 99% and Chi2 test for heterogeneity
P < 0.00001). In addition, women who received vitamin supple-
mentation on a daily basis reached a higher 25(OH)D levels at the
end of the pregnancy compared with women who received a single
dose (mean difference in 25(OH)D levels between groups of
37.7 nmol/L; 95% CI 28.3, 47.2). This response was also highly
heterogeneous ((Tau2 = 554.9, I2 = 99% and Chi2 test for heteroge-
neity P < 0.00001).Fig. 2. Forest plot of the effects of vitamin D sWith respect to preeclampsia, two trials [5,53] with 219 women
assessed this outcome. There was a trend for the effect of
supplementation whereas women receiving vitamin D supplemen-
tation had a lower risk of pre-eclampsia than women on the placebo
group (8.9% versus 15.5%; average risk ratio 0.52; 95% CI 0.25, 1.05).
The risk of gestational diabetes was assessed in two trials [5,53] with
219 women. Women taking vitamin D supplementation during
pregnancy had similar risk than those on the placebo group (average
risk ratio 0.43; 95% CI 0.05, 3.45).
With respect to adverse side effects, a single study including
135 women reported on this outcome [69], limiting our ability to
assess the safety of the intervention. No trials reported on our other
pre-speciﬁed maternal secondary outcomes: impaired glucose
tolerance; caesarean section; gestational hypertension or maternal
death.
3.3. Oral vitamin D and calcium supplements versus no treatment/
placebo (no vitamin or minerals)
There were six trials with 1688 women for this comparison
[6,19,34,41,42,61]. There were no studies reporting on maternal 25
(OH)D levels. The effects on pre-eclampsia were assessed in three
trials [6,41,61] with 1114 women. Results showed that vitamin D
supplementation signiﬁcantly reduced the risk of preeclampsia in
those receiving vitamin D and calcium supplementation combined
compared to those on placebo/control groups (5% versus 9%;
average risk ratio 0.51; 95% CI 0.32, 0.80). Only one study assessed
the effects on gestational diabetes [5,3]; therefore, no analysis was
done. In addition, no trials reported on our other pre-speciﬁed
maternal secondary outcomes.upplementation on serum 25(OH)D levels.
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This article summarizes an ongoing update of a previous
Cochrane review on vitamin D supplementation in pregnancy
[17]). We now included 15 trials (2833 women), nine of which
compared vitamin D alone versus no treatment or placebo while
six trials provided vitamin D plus calcium in comparison with no
treatment.
The main ﬁnding was that vitamin D supplementation during
pregnancy signiﬁcantly raised serum 25(OH)D levels at the end of
pregnancy, particularly if supplementation was daily versus
weekly, monthly or once. However, this response was highly
heterogeneous. These inconsistencies could be related to the
different doses used in the trials included and also in the difference
in methods to assess serum 25(OH)D. This biomarker is difﬁcult
and complex, with high variability in results between methods
used [27]. High performance liquid chromatography mass
spectrometry is the best available method [26] but only one trial
used this method. Therefore, results should be interpreted with
caution.
We also found that vitamin D supplementation, with or without
calcium, may reduce the risk of pre-eclampsia. Observational
studies have also found that maternal vitamin D deﬁciency in
pregnancy increases the risk of pre-eclampsia [59]. The mecha-
nism explaining this is not well known. The pathogenesis of
preeclampsia involves a number of biological processes that may
be directly or indirectly affected by vitamin D, including immune
dysfunction, placental implantation, abnormal angiogenesis,
excessive inﬂammation, and hypertension [8,9]. Also, in the only
2 studies reporting on gestational diabetes, no signiﬁcant effect of
vitamin D on this outcome was observed. Observational studies
have reported an association between maternal vitamin D
deﬁciency and gestational diabetes [21,70,1,66]. Therefore, more
studies are warranted.
The other maternal outcomes (impaired glucose tolerance,
caesarean section, gestational hypertension, side effects or death)
were either not reported or reported only by one trial; therefore,
we were not able to assess the effects of the intervention.
Observational studies have reported an association between
maternal vitamin D deﬁciency and caesarean section [43,54].
It is important to note that trials only comparing different
doses of vitamin D supplementation were not included in this
review. This was done to ﬁrst evaluate the biological rationale
for supplementing vitamin D during pregnancy against no
supplementation on functional pregnant outcomes, as routine
vitamin D supplementation is not widely done throughout the
world. Once this is clearly determined, future reviews should
evaluate the most optimal dose to use for signiﬁcant beneﬁcial
effects on these pregnancy outcomes. In fact, Hollis et al. [29]
and Hollis et al. [30] found signiﬁcant beneﬁcial effects of high
doses of vitamin D supplementation (4000 IU/d) compared to
lower dose (400 or 2000 IU/d) during pregnancy on pre-
eclampsia and caesarean section. There are currently about
15 trials and several others ongoing that could contribute data for
evaluating this.
In conclusion, further high quality rigorous randomized
trials are required to evaluate the role of vitamin D supplemen-
tation in functional outcomes of pregnancy and its safety.
Future research should evaluate if an increase of serum 25(OH)
D levels improve maternal outcomes in populations with
different degrees of body mass index, skin pigmentation and
settings. Information on the most effective and safe dosage,
supplementation regimen (daily, intermittent or single doses),
the timing of initiation of vitamin D supplementation, and the
effect of vitamin D when combined with other vitamins and
minerals are also needed to inform policy-making. To our bestknowledge there are currently 23 ongoing studies that, once
published, are likely to double the body of evidence identiﬁed for
this review. After their publication and overall assessment,
conclusions on the effects and safety of this intervention may be
updated.
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